PD-L1 expression as a potential predictive biomarker

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages 1285-1287

  Fusi, Alberto ^a   Festino, Lucia ^b   Botti, Gerado ^b   Masucci, Giuseppe ^d   Melero, Ignacio ^e   Lorigan, Paul ^a,c   Ascierto, Paolo A ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DACARBAZINE; DOCETAXEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; MELANOMA; NON SMALL CELL LUNG CANCER; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84953885167     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00307-1     Document Type: Note

References (10)

1. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16:375-384.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015, 372:2521-2532.
4. Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. Proc Am Soc Clin Oncol 2015, 33(suppl):9005. (abstr).
5. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous (non-SQ) cell non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2015, 33(suppl):LBA109. (abstr).
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015, 373:123-135.
7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med 2015, 373:23-34.
8. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
9. Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Proc Am Soc Clin Oncol 2015, 33(suppl):3001. (abstr).
10. Le DT, Uram JE, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. Proc Am Soc Clin Oncol 2015, 33(suppl):LBA100. (abstr).